ITLN1 suppresses colorectal cancer progression by inhibiting Wnt/β-catenin-mediated EMT and reprogramming macrophage...

Colorectal cancer (CRC) progression involves complex tumor-immune interactions. This study aimed to identify key prognostic genes and elucidate the role of ITLN1 in CRC progression and immune modulation.

The TCGA-CRC, GSE137511, and GSE141174 datasets were scrutinized for differentially expressed genes (DEGs). We evaluated overlapping DEGs applying LASSO Cox regression. qRT-PCR and WB assays have been utilized to confirm gene expression in CRC cell lines. After ITLN1 overexpression, functional investigations were performed utilizing cell viability assays, colony formation, migration, invasion assays, cell cycle and apoptosis analyses, as well as epithelial-mesenchymal transition (EMT)-related experiments. ITLN1's impact on the Wnt/β-catenin pathway was evaluated by WB, with LiCl applied for pathway reactivation. Furthermore, macrophage polarization assays were performed using THP-1-derived macrophages co-cultured with ITLN1-overexpressing or Intelectin-1-treated CRC cells.

LASSO analysis identified five prognostic genes (TIMP1, SLC35D1, ITLN1, HIGD1A, and SCGB2A1), and ITLN1 was consistently downregulated in CRC tissues and cell lines. Tumors and CRC cell lines showed a similar reduction in ITLN1. ITLN1 overexpression curtailed clonogenic growth, invasion, and migration, induced cell cycle arrest and apoptosis, suppressed EMT, and attenuated Wnt/β-catenin signaling; LiCl partially reversed these effects. Intelectin-1 decreased CRC cell viability with increased apoptosis and reprogrammed macrophages toward an M1 phenotype. Conditioned media from Intelectin-1 arms reduced CRC migration/invasion and EMT readouts, which were mitigated by LiCl.

ITLN1 inhibits CRC progression by inactivating the Wnt/β-catenin signaling pathway and reprogramming macrophages toward a tumor-suppressive M1 phenotype, highlighting its potential as a therapeutic target.